In 2006, a digital injector designed for growth hormone therapy was jointly developed by JCR Pharmaceuticals and PHC. Most of the patients undertaking growth hormone therapy are young children, and the patients themselves and their families require subcutaneous injections almost every day.
" We want to realize a user-friendly injector which encourages patients "
We began development with this thought in mind.

PHC makes this a reality through digital injectors, developing technologies based on patients’ needs that JCR Pharmaceuticals derived from their own medical treatment experiences. After its initial launch in 2006, PHC has been making efforts to improve its devices together with JCR Pharmaceuticals, resulting in a second generation device in 2012 and a third generation device in 2017. Furthermore, PHC launched its Medication Management App, Melon Nikki,* for use with the digital injector, in 2020.

We at PHC will continue to improve our digital injectors, aiming to contribute to patients' health throughout the world.

*Melon Nikki is a registered trademark of JCR Pharmaceuticals Co., Ltd.

About JCR Pharmaceuticals Co., Ltd

JCR is a specialty pharma company engaged in research, development, manufacturing, and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, “Contributing towards people’s healthcare through pharmaceutical products” drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient populations.
www.jcrpharm.co.jp/en/site/en/index.html